Micron Just Raised Its Buyback Authorization to $35 Billion. Prediction: It Spends More Buying Back Stock in the Next Year Than in the Past 8 Combined.

Micron raised its buyback authorization to $35.16 billion on Oct. 8, after spending $7.84 billion repurchasing shares over fiscal 2019–2026. The enlarged authorization is not a commitment to repurchase, and CHIPS Act funding terms constrain buybacks through Dec. 9, 2029; at roughly $985 per share, the full authorization would retire only about 35 million shares, or 3% of the 1.13 billion outstanding. Fiscal 2026 free cash flow was $62.3 billion, but rising employee share awards and sensitivity to memory prices may limit near-term per-share benefits.

Analysis

The authorization is a ceiling, not a committed bid. Its signal value is greater than its near-term EPS impact: it gives management discretion to return cash, but actual repurchases must compete with memory-cycle capex and are constrained by CHIPS Act terms. Treat it as a possible downside cushion, not a durable valuation floor.

The key second-order risk is procyclical capital allocation. If management buys aggressively while memory pricing and cash generation are unusually strong, it may retire fewer shares per dollar and have less flexibility when prices weaken and investment needs remain high. Employee equity issuance also means gross repurchases can overstate the reduction in diluted shares. The reported trailing earnings multiple is a poor anchor if earnings are near a cyclical peak; memory pricing and forward earnings revisions should dominate the multiple.

Over days, the authorization may support sentiment but is unlikely to outweigh memory-price news. Over 1–3 months, verify actual repurchases, diluted share-count change, and management’s cash-return comments alongside DRAM/NAND pricing and guidance. Over 6–18 months, the thesis depends on whether AI-driven demand sustains pricing without requiring enough capacity investment to crowd out returns. Upside to the buyback thesis: durable pricing and sustained post-investment cash generation. Falsifiers: weakening memory prices, lower guidance/FCF, or repurchases that fail to reduce diluted shares. The contrarian point: the headline size can look bullish while the economics of buying at peak-cycle prices are unattractive.

Key Decisions for Investors

• Do not buy MU solely on the authorization announcement; regard it as optional support, not a near-term EPS catalyst. Prefer waiting for evidence in quarterly repurchase disclosures and diluted shares outstanding.
• For existing MU exposure, monitor memory-price trends and forward guidance as the primary risk controls. A deterioration in pricing or FCF would outweigh the buyback signal and merits reducing exposure or hedging.
• Only treat the capital-return thesis as strengthening if actual repurchases persist after applicable CHIPS Act limits and net share count falls after employee awards; otherwise, downgrade the authorization’s value as a catalyst.
• No standalone trade is compelling from this news alone. Reassess after the next earnings update: sustained pricing and FCF would validate buybacks as incremental support; weaker pricing or cash generation would falsify the bullish read.